Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
140 hedge funds and large institutions have $792M invested in Intersect ENT, Inc in 2017 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 44 reducing their positions, and 13 closing their positions.
1,846% more call options, than puts
Call options by funds: $5.04M | Put options by funds: $259K
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
17% more capital invested
Capital invested by funds: $678M → $792M (+$114M)
16% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 44
9% more funds holding
Funds holding: 128 → 140 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.8M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.1M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.1M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
+$8.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$18.3M |
| 2 |
PC
Paulson & Co
New York
|
-$15.6M |
| 3 |
Millennium Management
New York
|
-$15.4M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$3.06M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.96M |
XENT Hedge Fund Activity: Q3 2017 in Review
140 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q3 2017, worth a combined $792M — up 17% from $678M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new XENT positions and 13 closed out — a net gain of 12 holders — while 51 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27.8M. The largest seller was Jennison Associates, cutting an estimated $18.3M.
- 140 institutional investors held Intersect ENT, Inc (XENT) as of Q3 2017, up from 128 in Q2 2017.
- Funds reported $792M of Intersect ENT, Inc stock for Q3 2017, up 17% quarter-over-quarter.
- 25 funds opened new Intersect ENT, Inc positions in Q3 2017 and 13 closed out, a net change of +12 holders.
- The largest Intersect ENT, Inc buyer in Q3 2017 was Fidelity Investments, an estimated $27.8M added.
- The largest Intersect ENT, Inc seller in Q3 2017 was Jennison Associates, an estimated $18.3M sold.
Based on aggregated 13F filings for Q3 2017.